GRI Bio Receives FDA Orphan Drug Designation for GRI-0621 in IPF

GRI Bio announced FDA Orphan Drug Designation for GRI-0621 (Tazarotene) to treat Idiopathic Pulmonary Fibrosis, a rare progressive lung disease. The designation provides potential seven-year U.S. market exclusivity, tax credits, and regulatory benefits that could accelerate development and create significant commercial value.